Bristol-Myers Squibb Company (FRA:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 78.07B |
| Revenue (ttm) | 40.62B |
| Net Income (ttm) | 4.30B |
| Shares Out | n/a |
| EPS (ttm) | 2.12 |
| PE Ratio | 18.16 |
| Forward PE | 7.02 |
| Dividend | 2.22 (5.99%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 1,716 |
| Average Volume | 712 |
| Open | 37.08 |
| Previous Close | 37.37 |
| Day's Range | 36.81 - 37.27 |
| 52-Week Range | 37.00 - 58.51 |
| Beta | n/a |
| RSI | 47.64 |
| Earnings Date | Oct 30, 2025 |
About FRA:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Validea Detailed Fundamental Analysis - BMY
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Earnings Yield Investor model based on the published stra...
Bristol Myers (BMY) Reports Positive Trial Data on Cancer Drug
Bristol Myers (BMY) Reports Positive Trial Data on Cancer Drug
Bristol Myers Squibb (BMY) Reports Promising Phase I Trial Results for Iza-bren
Bristol Myers Squibb (BMY) Reports Promising Phase I Trial Results for Iza-bren
Bristol Myers Squibb, SystImmune report data from lung cancer trial
HopeHealth Launches Phase 3 Clinical Trial Site To Advance Lupus Research With Support From Bristol Myers Squibb
First HopeHealth Clinical Trial Marks Major Milestone for Access to Medical Research in Rural South CarolinaOriginally published on HopeHealth NORTHAMPTON, MA / ACCESS Newswire / October 16, 2025 / Ho...
BMY Factor-Based Stock Analysis
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Earnings Yield Investor model based on the published stra...
BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment
Every Word Matters: The Next Chapter of Our Universal Patient Language
Originally published on BMS.com in recognition of Health Literacy Month, the following article highlights how Bristol Myers Squibb's Universal Patient Language (UPL) program is advancing clearer, more...
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.
Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics
Bristol Myers Squibb to Present Data at ESMO 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2025 to be held from O...
Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus
Get the latest on healthcare stocks, major acquisitions, legal cases, and policy updates impacting the market.
Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more
Stay updated on major M&A deals across biotech, fintech, and energy sectors this week. Discover key market moves and their impact.
Bristol Myers Squibb: Value Emerges From Distress
Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.
Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Acquisition
Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Acquisition
Bristol Myers Squibb (BMY) Expands with Orbital Therapeutics Acquisition
Bristol Myers Squibb (BMY) Expands with Orbital Therapeutics Acquisition
Bristol Myers (BMY) to Acquire Orbital Therapeutics in $1.5 Billion Deal
Bristol Myers (BMY) to Acquire Orbital Therapeutics in $1.5 Billion Deal
Bristol-Myers buys Orbital Therapeutics for $1.5 billion
Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash.
Bristol Myers Squibb to buy Orbital Therapeutics for $1.5B in cash
Bristol Myers Squibb and National Community Pharmacists Association Pilot Rural Heart Health Care Initiatives
BMS and NCPA to address cardiovascular disease and enhance patient care coordination with specialized training in rural Alabama, Arkansas, Kentucky, Louisiana, Mississippi, and Missouri pharmaciesOrig...
Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield
BMY November 28th Options Begin Trading
Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the November 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the B...
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.